Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $55 from $52 and keeps an Outperform rating on the shares. The company’s Q1 results illustrate its “impressive” commercial execution in the early phases of Attruby’s launch in transthyretin amyloid cardiomyopathy, the analyst tells investors. The firm is raising its price target to reflect its updated Attruby sales expectations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $72 from $65 at UBS
- BridgeBio price target raised to $50 from $46 at BofA
- Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
- BridgeBio price target raised to $63 from $46 at Piper Sandler
- BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50